Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

CBP-307

Small molecule · developed by Connect Biopharm LLC

Phase 2 Most advanced trial (none active)

CNTB Developer

2 Registered trials

What is CBP-307?

CBP-307 is an orally administered capsule studied in moderate to severe ulcerative colitis and autoimmune diseases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Immunology
Developer: Connect Biopharm LLC (CNTB)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04700449	Phase 2	Moderate to Severe Ulcerative Colitis	Completed	CNTB
NCT04818229	Phase 1	Autoimmune Diseases	Completed	CNTB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Autoimmune DiseasesModerate to Severe Ulcerative Colitis

More from Connect Biopharm LLC

CBP-174 Phase 1 CBP-201 Phase 3 Rademikibart Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CNTB page.

Follow CNTB, the company behind CBP-307

See CNTB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CNTB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z